Format

Send to

Choose Destination
Oncoimmunology. 2015 Feb 3;4(5):e1003012. eCollection 2015 May.

Expression profile of the human IDO1 protein, a cancer drug target involved in tumoral immune resistance.

Author information

1
Ludwig Institute for Cancer Research ; Brussels, Belgium ; WELBIO (Walloon Excellence in Life Sciences and Biotechnology) ; Brussels, Belgium ; de Duve Institute, Université catholique de Louvain , Brussels, Belgium.
2
Ludwig Institute for Cancer Research ; Brussels, Belgium ; de Duve Institute, Université catholique de Louvain , Brussels, Belgium.

Abstract

Tryptophan catabolism by indoleamine 2,3-dioxygenase (IDO1) is a physiological immunoregulatory mechanism often hijacked by tumors. Our recent extensive study of IDO1 protein expression in human tissues showed expression in mature dendritic cells and in pulmonary and placental endothelial cells. IDO1 was also expressed in 56% of tumors, either by tumoral, stromal, or endothelial cells. These results and reagent will guide the clinical development of IDO1 inhibitors for cancer therapy.

KEYWORDS:

dendritic cells; immunohistochemistry; immunosuppression; indoleamine 2,3-dioxygenase; tryptophan; tumor

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center